p16 negative oropharyngeal cancer
T 分期 =>
Tx: 腫瘤無法評估
Tis: 原位癌(carcinoma in situ)
T1: 腫瘤小於等於2公分
T2: 腫瘤大於2公分, 小於等於4cm
T3: 腫瘤大於4公分或是侵犯到epiglottis 的 lingual surface
T4a:腫瘤侵犯到larynx, tongue的extrinsic muscle, medial pterygoid, hard palate or mandible
T4b:腫瘤侵犯到lateral pterygoid, pterygoid plates, lateral nasopharynx, skull base or encase carotid artery
N 分期 => 和口腔癌一樣的N分期(臨床跟病理有不同的N分期)
clinical N stage:
N1: 同側單顆, ≤ 3cm, ENE(-)
N2a: 同側單顆, >3cm, ≤ 6cm, ENE(-)
N2b: 同側多顆, ≤ 6cm, ENE(-)
N2c: 雙側或對側, ≤ 6cm, ENE(-)
N3a: >6cm, ENE(-)
N3b: 臨床上明顯有ENE(不能只靠影像,還要加上理學檢查支持)
P.S. ENE=extranodal extension
pathological N stage:
N1: 同側單顆, ≤ 3cm, ENE(-)
N2a: 同側單顆, ≤ 3cm, ENE(+) or 同側單顆, >3cm, ≤ 6cm, ENE(-)
N2b: 同側多顆, ≤ 6cm, ENE(-)
N2c: 雙側或對側, ≤ 6cm, ENE(-)
N3a: >6cm, ENE(-)
N3b: 同側單顆, > 3cm, ENE(+) or 多顆, ENE(+) or 對側單顆, ENE(+)
M分期:
M0: 沒有遠端轉移
M1: 有遠端轉移
prognostic stage:
|
N0 |
N1 |
N2 |
N3 |
T1 |
I |
III |
IVA |
IVB |
T2 |
II |
III |
IVA |
IVB |
T3 |
III |
III |
IVA |
IVB |
T4a |
IVA |
IVA |
IVA |
IVB |
T4b |
IVB |
IVB |
IVB |
IVB |
M1 => stage IVC
p16 positive oropharyngeal cancer
T 分期 =>
T0: 腫瘤無法評估
T1: 腫瘤小於等於2公分
T2: 腫瘤大於2公分, 小於等於4cm
T3: 腫瘤大於4公分或是侵犯到epiglottis 的 lingual surface
T4: 腫瘤侵犯到larynx, tongue的extrinsic muscle, medial pterygoid, hard palate or mandible 或更深
N分期 => 可以分成臨床和病理N分期(注意跟p16 negative oropharyngeal cancer 明顯不同,不看ENE)
clinical N stage:
NX: 局部淋巴結無法評估
N0: 沒有局部淋巴結侵犯
N1: 一或多顆同側淋巴結侵犯, 都小於等於6 cm
N2: 對側或雙側側淋巴結侵犯, 都小於等於6 cm
N3: 淋巴結大於6cm
pathological N stage:
NX: 局部淋巴結無法評估
N0: 沒有局部淋巴結侵犯
N1: 侵犯淋巴結小於等於4顆
N2: 侵犯淋巴結大於4顆
M分期:
M0: 沒有遠端轉移
M1: 有遠端轉移
prognostic stage groups: 可以分成臨床和病理
clinical:
|
N0 |
N1 |
N2 |
N3 |
T0 |
I |
I |
II |
III |
T1 |
I |
I |
II |
III |
T2 |
I |
I |
II |
III |
T3 |
II |
II |
II |
III |
T4 |
III |
III |
III |
III |
M1 => stage IV
pathological:
|
N0 |
N1 |
N2 |
T0 |
I |
I |
II |
T1 |
I |
I |
II |
T2 |
I |
I |
II |
T3 |
II |
II |
III |
T4 |
II |
II |
III |
M1 => stage IV
reference:
1. NCCN guideline
2. Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014;32(34):3858-3866. doi:10.1200/JCO.2014.55.3925
沒有留言:
張貼留言